Literature DB >> 31180250

Cognitive and behavioral assessment in Parkinson's disease.

Saul Martinez-Horta1,2,3,4, Andrea Horta-Barba1,2,3, Jaime Kulisevsky1,2,3,4.   

Abstract

Introduction: Cognitive impairment and behavioral disturbances are common findings in Parkinson's disease (PD). Despite initially being considered late complications of the disease, it is currently accepted that almost all PD patients will exhibit cognitive and behavioral abnormalities from the early and even the premotor stages of the disease. Areas covered: The present review focuses on the cognitive profile of PD, the clinical picture of PD-MCI and dementia in PD (PDD) and the recommended methods for cognitive assessment in this population. The authors also describe the more representative neuropsychiatric alterations and provide an overview of the recommended methods of assessment. Expert opinion: Cognitive and behavioral symptoms are inherent to PD, appear in a vast majority of patients at some point during disease progression and have an enormous impact on health-related quality of life of patients and caregivers. Validated methods of cognitive and behavioral assessment are currently developed and must be used in research and clinical settings.

Entities:  

Keywords:  PD-MCI; Parkinson’s disease; assessment; cognition; neuropsychiatric symptoms

Mesh:

Year:  2019        PMID: 31180250     DOI: 10.1080/14737175.2019.1629290

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  3 in total

1.  Optimization of cognitive assessment in Parkinsonisms by applying artificial intelligence to a comprehensive screening test.

Authors:  Paola Ortelli; Davide Ferrazzoli; Viviana Versace; Veronica Cian; Marianna Zarucchi; Anna Gusmeroli; Margherita Canesi; Giuseppe Frazzitta; Daniele Volpe; Lucia Ricciardi; Raffaele Nardone; Ingrid Ruffini; Leopold Saltuari; Luca Sebastianelli; Daniele Baranzini; Roberto Maestri
Journal:  NPJ Parkinsons Dis       Date:  2022-04-11

2.  A Randomized Clinical Trial to Evaluate the Effects of Safinamide on Apathetic Non-demented Patients With Parkinson's Disease.

Authors:  Jaime Kulisevsky; Saul Martínez-Horta; Antonia Campolongo; Berta Pascual-Sedano; Juan Marín-Lahoz; Helena Bejr-Kasem; Ignacio Aracil-Bolaños; Andrea Horta-Barba; Arnau Puig-Davi; Javier Pagonabarraga
Journal:  Front Neurol       Date:  2022-06-02       Impact factor: 4.086

Review 3.  Curcumin Formulations and Trials: What's New in Neurological Diseases.

Authors:  Stella Gagliardi; Carlo Morasso; Polychronis Stivaktakis; Cecilia Pandini; Veronica Tinelli; Aristides Tsatsakis; Davide Prosperi; Miriam Hickey; Fabio Corsi; Cristina Cereda
Journal:  Molecules       Date:  2020-11-18       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.